Literature DB >> 10857762

Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?

P L Podolin1, M B Wilusz, R M Cubbon, U Pajvani, C J Lord, J A Todd, L B Peterson, L S Wicker, P A Lyons.   

Abstract

The insulin-dependent diabetes (Idd) gene, Idd3, has been localised to a 0.35 cM region of chromosome 3 containing the structural gene for the cytokine interleukin 2 (IL-2). While variation of the N-terminal amino acid sequence of IL-2 has been shown to correlate with Idd3 allelic variation, differences in induction of proliferation by IL-2 allotypes have not been detected. In the current study, we examined the electrophoretic migration of IL-2 allotypes and have found two distinct patterns, consistent with differences in glycosylation, that correlate with diabetes-resistance and susceptibility. These findings strongly suggest that IL-2 variants may be functionally distinct.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10857762     DOI: 10.1006/cyto.1999.0609

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  17 in total

1.  Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.

Authors:  Jun Yamanouchi; Dan Rainbow; Pau Serra; Sarah Howlett; Kara Hunter; Valerie E S Garner; Andrea Gonzalez-Munoz; Jan Clark; Riitta Veijola; Rose Cubbon; Show-Ling Chen; Raymond Rosa; Anne Marie Cumiskey; David V Serreze; Simon Gregory; Jane Rogers; Paul A Lyons; Barry Healy; Luc J Smink; John A Todd; Laurence B Peterson; Linda S Wicker; Pere Santamaria
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

2.  Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping.

Authors:  P A Lyons; N Armitage; F Argentina; P Denny; N J Hill; C J Lord; M B Wilusz; L B Peterson; L S Wicker; J A Todd
Journal:  Genome Res       Date:  2000-04       Impact factor: 9.043

Review 3.  Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.

Authors:  John P Driver; David V Serreze; Yi-Guang Chen
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

4.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

5.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

6.  Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus.

Authors:  Helen M McGuire; Alexis Vogelzang; Natasha Hill; Malin Flodström-Tullberg; Jonathan Sprent; Cecile King
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

7.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

Review 8.  Insulin as an autoantigen in NOD/human diabetes.

Authors:  Li Zhang; Maki Nakayama; George S Eisenbarth
Journal:  Curr Opin Immunol       Date:  2008-02       Impact factor: 7.486

9.  A novel mouse Chromosome 2 congenic strain with obesity phenotypes.

Authors:  Adam L Diament; Poupak Farahani; Sally Chiu; Janis Fisler; Craig H Warden
Journal:  Mamm Genome       Date:  2004-06       Impact factor: 2.957

10.  Cutting edge: the Idd3 genetic interval determines regulatory T cell function through CD11b+CD11c- APC.

Authors:  Ana C Anderson; Rucha Chandwaskar; David H Lee; Vijay K Kuchroo
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.